CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis

Dong Hyun Jo, Dong Woo Song, Chang Sik Cho, Un Gi Kim, Kyu Jun Lee, Kihwang Lee, Sung Wook Park, Daesik Kim, Jin Hyoung Kim, Jin Soo Kim, Seokjoong Kim, Jeong Hun Kim, Jung Min Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Leber congenital amaurosis (LCA), one of the leading causes of childhood-onset blindness, is caused by autosomal recessive mutations in several genes including RPE65. In this study, we performed CRISPR-Cas9–mediated therapeutic correction of a disease-associated nonsense mutation in Rpe65 in rd12 mice, a model of human LCA. Subretinal injection of adeno-associated virus carrying CRISPR-Cas9 and donor DNA resulted in >1% homology-directed repair and ~1.6% deletion of the pathogenic stop codon in Rpe65 in retinal pigment epithelial tissues of rd12 mice. The a- and b-waves of electroretinograms were recovered to levels up to 21.2 ± 4.1% and 39.8 ± 3.2% of their wild-type mice counterparts upon bright stimuli after dark adaptation 7 months after injection. There was no definite evidence of histologic perturbation or tumorigenesis during 7 months of observation. Collectively, we present the first therapeutic correction of an Rpe65 nonsense mutation using CRISPR-Cas9, providing new insight for developing therapeutics for LCA.

Original languageEnglish
Article numbereaax1210
JournalScience Advances
Volume5
Issue number10
DOIs
StatePublished - 30 Oct 2019

Fingerprint

editing
phenotype
mutations
mice
dark adaptation
blindness
injection
deletion
homology
viruses
pigments
genes
stimuli
deoxyribonucleic acid
perturbation
causes

Cite this

Jo, Dong Hyun ; Song, Dong Woo ; Cho, Chang Sik ; Kim, Un Gi ; Lee, Kyu Jun ; Lee, Kihwang ; Park, Sung Wook ; Kim, Daesik ; Kim, Jin Hyoung ; Kim, Jin Soo ; Kim, Seokjoong ; Kim, Jeong Hun ; Lee, Jung Min. / CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis. In: Science Advances. 2019 ; Vol. 5, No. 10.
@article{044040b7d4e349fb8d0ebad6b43234f5,
title = "CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis",
abstract = "Leber congenital amaurosis (LCA), one of the leading causes of childhood-onset blindness, is caused by autosomal recessive mutations in several genes including RPE65. In this study, we performed CRISPR-Cas9–mediated therapeutic correction of a disease-associated nonsense mutation in Rpe65 in rd12 mice, a model of human LCA. Subretinal injection of adeno-associated virus carrying CRISPR-Cas9 and donor DNA resulted in >1{\%} homology-directed repair and ~1.6{\%} deletion of the pathogenic stop codon in Rpe65 in retinal pigment epithelial tissues of rd12 mice. The a- and b-waves of electroretinograms were recovered to levels up to 21.2 ± 4.1{\%} and 39.8 ± 3.2{\%} of their wild-type mice counterparts upon bright stimuli after dark adaptation 7 months after injection. There was no definite evidence of histologic perturbation or tumorigenesis during 7 months of observation. Collectively, we present the first therapeutic correction of an Rpe65 nonsense mutation using CRISPR-Cas9, providing new insight for developing therapeutics for LCA.",
author = "Jo, {Dong Hyun} and Song, {Dong Woo} and Cho, {Chang Sik} and Kim, {Un Gi} and Lee, {Kyu Jun} and Kihwang Lee and Park, {Sung Wook} and Daesik Kim and Kim, {Jin Hyoung} and Kim, {Jin Soo} and Seokjoong Kim and Kim, {Jeong Hun} and Lee, {Jung Min}",
year = "2019",
month = "10",
day = "30",
doi = "10.1126/sciadv.aax1210",
language = "English",
volume = "5",
journal = "Science Advances",
issn = "2375-2548",
number = "10",

}

Jo, DH, Song, DW, Cho, CS, Kim, UG, Lee, KJ, Lee, K, Park, SW, Kim, D, Kim, JH, Kim, JS, Kim, S, Kim, JH & Lee, JM 2019, 'CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis', Science Advances, vol. 5, no. 10, eaax1210. https://doi.org/10.1126/sciadv.aax1210

CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis. / Jo, Dong Hyun; Song, Dong Woo; Cho, Chang Sik; Kim, Un Gi; Lee, Kyu Jun; Lee, Kihwang; Park, Sung Wook; Kim, Daesik; Kim, Jin Hyoung; Kim, Jin Soo; Kim, Seokjoong; Kim, Jeong Hun; Lee, Jung Min.

In: Science Advances, Vol. 5, No. 10, eaax1210, 30.10.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis

AU - Jo, Dong Hyun

AU - Song, Dong Woo

AU - Cho, Chang Sik

AU - Kim, Un Gi

AU - Lee, Kyu Jun

AU - Lee, Kihwang

AU - Park, Sung Wook

AU - Kim, Daesik

AU - Kim, Jin Hyoung

AU - Kim, Jin Soo

AU - Kim, Seokjoong

AU - Kim, Jeong Hun

AU - Lee, Jung Min

PY - 2019/10/30

Y1 - 2019/10/30

N2 - Leber congenital amaurosis (LCA), one of the leading causes of childhood-onset blindness, is caused by autosomal recessive mutations in several genes including RPE65. In this study, we performed CRISPR-Cas9–mediated therapeutic correction of a disease-associated nonsense mutation in Rpe65 in rd12 mice, a model of human LCA. Subretinal injection of adeno-associated virus carrying CRISPR-Cas9 and donor DNA resulted in >1% homology-directed repair and ~1.6% deletion of the pathogenic stop codon in Rpe65 in retinal pigment epithelial tissues of rd12 mice. The a- and b-waves of electroretinograms were recovered to levels up to 21.2 ± 4.1% and 39.8 ± 3.2% of their wild-type mice counterparts upon bright stimuli after dark adaptation 7 months after injection. There was no definite evidence of histologic perturbation or tumorigenesis during 7 months of observation. Collectively, we present the first therapeutic correction of an Rpe65 nonsense mutation using CRISPR-Cas9, providing new insight for developing therapeutics for LCA.

AB - Leber congenital amaurosis (LCA), one of the leading causes of childhood-onset blindness, is caused by autosomal recessive mutations in several genes including RPE65. In this study, we performed CRISPR-Cas9–mediated therapeutic correction of a disease-associated nonsense mutation in Rpe65 in rd12 mice, a model of human LCA. Subretinal injection of adeno-associated virus carrying CRISPR-Cas9 and donor DNA resulted in >1% homology-directed repair and ~1.6% deletion of the pathogenic stop codon in Rpe65 in retinal pigment epithelial tissues of rd12 mice. The a- and b-waves of electroretinograms were recovered to levels up to 21.2 ± 4.1% and 39.8 ± 3.2% of their wild-type mice counterparts upon bright stimuli after dark adaptation 7 months after injection. There was no definite evidence of histologic perturbation or tumorigenesis during 7 months of observation. Collectively, we present the first therapeutic correction of an Rpe65 nonsense mutation using CRISPR-Cas9, providing new insight for developing therapeutics for LCA.

UR - http://www.scopus.com/inward/record.url?scp=85074593677&partnerID=8YFLogxK

U2 - 10.1126/sciadv.aax1210

DO - 10.1126/sciadv.aax1210

M3 - Article

C2 - 31692906

AN - SCOPUS:85074593677

VL - 5

JO - Science Advances

JF - Science Advances

SN - 2375-2548

IS - 10

M1 - eaax1210

ER -